Add To Watchlist
Share URL
About The Company
Description
Rigel Pharmaceuticals, Inc.
Read More
Overview
Value
1
Growth
59
Health
32
Management
39
Analyst Opinion
54
Total
36
All Scores Out Of 100
Best Features
- Low preportion of income is paid as dividend 0
Risk Factors
- Overvalued on cashflow basis
- Earnings have declined recently
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders 0
- No margin of safety at their current market price
- Disliked by Twitter users
Latest News

Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023
Seeking Alpha | 19:44 Fri 30 Dec 2022
Read More →

Don't Invest in Penny Stocks Until You've Read This Article
PennyStocks | 16:00 Sun 4 Dec 2022
Read More →

Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
Zacks Investment Research | 19:18 Fri 2 Dec 2022
Read More →

Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
InvestorPlace | 16:17 Fri 2 Dec 2022
Read More →
Market Peers
RIGL
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-196.75%
Revenue Growth (5 Year Average)
22.03%
Ratings Consensus
Neutral
Share Buybacks
-1.68%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 1.8 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-22.92%
PE/Earnings Growth
N/A
Price/Book
-15.69x
Growth
Growth Score
59
- ✔ 5 Year Average Revenue growth of 22.03% is higher than the market average (10.97%)
- ✔ 5 Year Average Earnings growth of 21.39% is higher than the market average (14.48%)
- ✘ Revenue growth has slowed this year
- ✘ Earnings growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of 0.39% is lower than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
22.03%
Earnings Growth
21.39%
Cashflow Growth
0.39%
Health
Health Score
32
Altman Z Score
N/A
Piostroski Score
1.00
Debt/Equity
1.01x
Current Assets/Liabilities
2.43x
Free Cashflow/Total Debt
0.17x
Debt/Capital
0.20x
Management
Management Score
39
Average Buybacks/Dilution
-1.68%
Recent Buybacks/Dilution
2.42%
5 Year Price Volitility
27.92%
Return On Assets
-11.36%
Return On Capital Employed
-4.39%
Return On Equity
-62.59%
Return On Free Cashflow
35.57%
Return On Investments
N/A
Analysts
Analyst Opinion
54
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Rigel Pharmaceuticals, Inc.
Currency
USD
Beta
0.73596
Vol Avg
3818514
Ceo
Mr. Raul Rodriguez
Cik
0001034842
Cusip
766559603
Exchange
NASDAQ Global Select
Full Time Employees
165
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2000-11-29
Address
1180 Veterans Blvd
City
South San Francisco
State
CALIFORNIA
Country
US
Zip
94080
Phone
16506241100
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
30
Twitter Sentiment
N/A
Stocktwits Sentiment
59.00